Live updates
Demis Hassabis's drug-design AI company Isomorphic Labs raises $5 billion, 2.4 times its May round, with Sequoia and a16z joining
First seen on X 6 hours ago@demishassabis ♥ 3,30011 views
Isomorphic Labs, the AI drug-discovery company led by Google DeepMind CEO Demis Hassabis, has raised $5 billion in a Series C round. It comes six months after the company raised $2.1 billion in May.
Greenoaks and Sequoia Capital co-led the oversubscribed round, alongside Andreessen Horowitz (a16z), several other new investors and parent Alphabet, the company said in a release on Nov 17. All existing investors, including Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund, also took part. Isomorphic said candidates designed with its in-house drug design engine, IsoDDE, are showing positive preclinical results in oncology and immunology, and that the money will help push its first programs toward clinical trials. "Our drug design engine is generating molecules with unprecedented precision and speed," Hassabis said. The company did not disclose a valuation; The Times of London reported it is now worth $50 billion. Spun out of DeepMind in 2021, Isomorphic has raised $7.7 billion since its first outside round of $600 million in March 2025.
Comments 0
Select a sentence in the story (long-press on phones) to comment on it.
“Thrilled to announce $5B in funding for @IsomorphicLabs to accelerate our mission to Solve All Disease.”
